Aging
Navigate
Back to articleFigure 3(3 of 12)
100%
Figure 3
Figure 3.The levels of MTFR1 have a significant difference in the clinicopathological features of patients with LAC. (A) Age; (B) Gender; (C) Smoking; (D) T stage; (E, F) Treatment effects. Abbreviation: LAC: lung adenocarcinoma; *P < 0.05; **P < 0.01; ***P < 0.001.
Figure 3 — Overexpression of MTFR1 promotes cancer progression and drug-resistance on cisplatin and is related to the immune microenvironment in lung adenocarcinoma | Aging